Italian pharma company Recordati S.p.A agreed to acquire the global rights to Enjaymo (sutimlimab) from Sanofi SA (NASDAQ:SNY ...

Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold ...

The deal includes additional commercial milestone payments of up to $250 million and will be completed by year-end, subject ...

As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. | Recordati is floating ...

Under the deal announced Friday, the Italian pharma will make an upfront payment of $825 million to Sanofi for global rights ...

Recordati will acquire global rights to Enjaymo from Sanofi for $825M, boosting its rare disease portfolio. The deal includes ...

Recordati SpA is shelling out $825 million up front for global rights to Enjaymo (sutimlimab), the only therapy approved for treating the rare disease cold agglutinin disease. In the deal with Sanofi ...

Sanofi (SNY) sells global rights to Enjaymo treatment for cold agglutinin disease to Recordati (RCDTF) in a deal worth up to ...

Recordati reached an agreement with French pharmaceutical company Sanofi to acquire the global rights to autoimmune disorder treatment Enjaymo for $825 million. The Italian pharmaceutical company said ...

Recordati 's (BIT: RECI) shares jumped on Friday following its deal with Sanofi (NASDAQ: SNY) to buy the global rights to ...

Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic ...

Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to ...